Plagril A tabs 75mg + 75mg #30

Instruction for Plagril A

Reed more and buy Plagril A here

Plagril A slows down the aggregation of platelets and red blood cells called erythrocytes, and also helps to reduce their adhesion and adhesion to the cell layer lining the inner surface of blood, lymph vessels and cardiac cavities. Also, the drug affects the surface tension of the membranes of red blood cells, facilitating their deformation when passing through the capillaries, and also improves blood flow. Numerous reviews about Plagril A, left by patients on various medical resources, confirm the effectiveness of the drug and note that, according to the results of monitoring their health, not only the prevention of platelet adhesion, but also the separation of the already formed clots was observed. The price of Plagril A is relatively affordable. When comparing it with analogues with a similar composition, we can say that there are drugs that are slightly cheaper and those whose price is several times higher than the cost of the described drug.

Release form, composition and packaging

Plagril A is sold in carton packs where the number of capsules is 30, 60, 100 and 200 pieces. 1 blister contains 10 microcapsules. The active and auxiliary substances are enclosed in a capsule, the mechanism, form and nature of release of which differs from standard drugs. The pill is placed in a hard white gelatinous shell, marked with the manufacturer's trademark and the name of the drug. The tablet itself has a capsule-like shape, painted in a pinkish or white tint. The active ingredients of the drug are two substances called clopidogrel and aspirin (acetylsalicylic acid), each with a dosage of 75 milligrams. Auxiliary components of coated pills: - film: MCC, mannitol, sodium croscarmellose, castor oil and dyes; - enteric: lactose monohydrate, modified starch, E330, E551, octadecanoic acid, E171, hypromellose.

Pharmachologic effect

The drug Plagril A has a combined composition. Its components have an antiplatelet effect, preventing the formation of blood clots. The active ingredient in the drug, called clopidogrel, reduces the ability of platelets to stick together. It forms bonds with adenosine diphosphate receptors and slows down their reaction with adenosine phosphates. Since this substance acts with receptor structures, it has an irreversible effect on them. As a result, platelets lose their functionality and recover only after a gradual renewal, on average, not earlier than 1 week. The effect of the application is noted after 2 hours from the moment the drug enters the body and depends on the dosage. With repeated admission, there is a significant slowdown in the process of gluing platelets. A tangible effect of the drug is observed on days 3-7 of therapy, while the inhibition rate is in the range of 40-60%. The return to the initial level of aggregation occurs after 1 week of suspension of treatment with this drug. Aspirin, which is the second active substance, acts on cyclooxygenase and slows down its enzymatic reactions. It reduces the concentration of thromboxane, which speeds up the process of platelet adhesion and contributes to the narrowing of the lumen of blood vessels. When combined with clopidogrel, an increase in the effectiveness of acetylsalicylic acid is noted and the result of treatment is achieved faster. The formation of blood clots is prevented, which subsequently attach to the arteries and blood vessels, provoking their blockage.

Indications

In the description of the drug Plagril A it is indicated that it should be taken if the following indications are present: - the need for the simultaneous intake of substances such as acetylsalicylic acid and clopidogrel; - prevention of the development of diseases of large arteries arising from the accumulation of lipids, as well as inflammation of smooth muscle cells; - acute coronary syndrome in patients with unstable angina pectoris, heart attack, as well as those who have undergone stenting and thrombolysis; - atrial fibrillation in patients predisposed to the formation of cardiovascular pathologies and unable to take medications that have an indirect effect on blood clotting; - stroke prevention.

Dosage

Plagril A is intended for oral administration. It must be taken once a day at any time convenient for this (before, after or during eating). Therapy of acute coronary syndrome with this medicine should begin with the first manifestations of the symptoms of the disease. A preliminary test is taken of two drugs, namely aspirin, with a dosage of 75 to 325 mg per day, and clopidogrel (300 mg). Patients with a heart attack also require testing for interaction with thrombolytic agents. For them, aspirin cannot be prescribed in doses exceeding the 100 mg mark. Patients over 75 years of age do not need a loading dose of clopidogrel. With unstable angina pectoris and myocardial infarction, the clinically noticeable effect of this drug is noted after a three-month course of treatment. The maximum duration of therapy can be up to 1 year. Patients who have a delayed enzymatic reaction of cytochrome P450 should be prescribed the drug as follows: the initial loading dosage is 600 mg, and then a daily intake of 150 mg at a time.

Contraindications

The list of contraindications for treatment with Plagril A includes: - excessive susceptibility to active and additional components; - lactose deficiency and glucose-galactose malabsorption; - abnormalities in the functioning of the liver in severe form; - severe malfunctions of the kidneys; - the patient has acute hemorrhage, including in the skull or from peptic ulcers present in the stomach and esophagus; - asthma provoked by treatment with non-steroidal anti-inflammatory drugs and salicylates, arising from chronic inflammation of the respiratory tract, as well as its combination with a runny nose and polyposis lesions of the nasal cavity and surrounding sinuses; - the patient has a rare disease characterized by the proliferation and accumulation of mast cells in the tissues of the body and / or bone marrow, in which aspirin therapy causes serious consequences, in particular, serious side symptoms and complications; - I-III trimester of bearing a baby; - the period of breastfeeding; - the patient does not reach the age of 18. Plagril A should be taken with extreme caution by patients with: - moderate liver disorders, as well as a predisposition to hemorrhage formation; - mild to moderate kidney malfunction; - after an injury or surgery; - pathologies that can provoke the development of hemorrhages, in particular, erosive and ulcerative lesions of the gastrointestinal tract or inside the eyes; - impaired blood circulation in the brain and stroke; - diseases, therapy of which is carried out with the help of non-steroidal anti-inflammatory drugs, in particular drugs that slow down the enzymatic reaction of cyclooxygenase; - the risk of developing an allergic reaction to aspirin and asthma caused by airway inflammation; - a predisposition to gout or a history of it; - impaired activity of cytochrome P450.

Side effects

Treatment with Plagril A is often accompanied by the development of hemorrhages into the subcutaneous layers, muscle, bone tissues, joints, the connective membrane of the eyes and retina, respiratory tract, nasal passages, gastrointestinal tract, abdominal cavity, brain, etc. The patients showed changes in clinical blood parameters, regular headaches, a feeling of loss of balance, numbness of the extremities, impaired taste, pain in the epigastric region, urge to vomit and vomiting itself, increased gas production, disturbances in intestinal motility and the appearance of colic in it, ulcerative lesions stomach, inflammation of the pancreas, oral mucosa and esophagus. In some patients, treatment with the drug was accompanied by the development of hepatitis, abnormalities in the liver in an acute form, skin rashes and itching, erythema, dermatitis, necrotic tissue lesions, urticaria, Quincke's edema, anaphylaxis, autoimmune reactions, malfunction of consciousness and incorrect perception of the environment, cardiovascular vascular pathologies. It is also possible the appearance of spastic contractions of the bronchi, inflammation and edema of the lungs, muscle, joint and bone pain, malfunctioning of the urinary system, in particular of the kidneys, pathological changes in the chest with hypertrophy of the glands and adipose tissue, a decrease in the concentration of glucose in the blood, gout, hearing impairment, increasing the concentration of creatinine, as well as fever.

Use by pregnant and breastfeeding women

Taking Plagril A during the period of gestation and subsequent breastfeeding is prohibited. If necessary, therapy with this drug during lactation should be discarded from breastfeeding.

Application for children

Plagril A cannot be used by patients under the age of 18.

Special instructions

Elderly patients can take this medication in a standard amount without reducing the dosage. Since the drug can provoke the development of hemorrhages, if there is a suspicion of its occurrence, the patient's condition should be monitored immediately. Before carrying out a planned surgical intervention, the use of Plagril A should be discontinued for a week, in the absence of an urgent need to obtain a pronounced antithrombotic effect. The medicine lengthens the duration of bleeding, about which the patient must be warned without fail. In some patients, clopidogrel therapy provoked the development of thrombocytopenia and hemolytic anemia, accompanied by neurological pathological processes, fever and malfunctioning of the kidneys. Therefore, when such a condition occurs, immediate treatment with the use of plasmapheresis is required. Patients who have had a stroke should be extremely careful with this drug, since there is a high risk of hemorrhage. According to clinical trials and studies, the drug can be taken by patients who drive vehicles and other responsible mechanisms. Nevertheless, in the event of negative side symptoms that affect the degree of concentration, the work of the central nervous system and the organs of visual perception, it is required to immediately abandon this kind of activity.

Overdose

In patients who have taken an excessive amount of this agent, the development of hemorrhages and the corresponding consequences may be observed. It is also possible the appearance of confusion, malfunctions of the organs of auditory perception, disorders of the digestive system, cephalalgia, etc. There is no drug that fully binds the action of Plagril A. Therapy should be carried out based on the symptoms manifested.

Drug interactions

Treatment with Plagril A in conjunction with thrombolytics or drugs that slow down the reaction of glycoprotein IIb / IIIa requires caution. Clopidogrel should also be taken with heparin with extreme caution, since their interaction increases the risk of hemorrhage. This drug can be used with indirect anticoagulants, but with precautions. With the combined use of this drug with non-steroidal anti-inflammatory drugs, the occurrence of latent hemorrhages in the gastrointestinal tract was noted, therefore it is better to refuse such an interaction. Taking clopidogrel with selective serotonin reuptake inhibitors is possible, but with caution. There is a normal interaction of atenolol, nifedipine, cimetidine, phenobarbital, estrogen-containing agents, digoxin, antacids, theophylline, phenytoin and tolbutamide with clopidogrel. Aspirin, when combined with agents aimed at lowering the level of uric acid in the body, reduces the effectiveness of the latter. With methotrexate, metamizole and acetazolamide, Plagril A must be taken with extreme caution.

Terms and conditions of storage

Keep Plagril A away from children, sunlight and moisture. During storage, it is necessary to ensure the temperature regime established by the manufacturer, not exceeding the mark of + 25 ° C. If the above conditions are observed, the medicine is suitable for 3 years from the date of manufacture.

Terms of sell

You can buy Plagril A without a prescription.